biospace.com· Annalee Armstrong·· 4 hours agoPickScore69
AstraZeneca bulks up MASH, cardio work in up to $1.5B AI partnership with insitro
AstraZeneca bulks up MASH, cardio work in up to $1.5B AI partnership with insitro
In brief
AstraZeneca will pay insitro up to $1.5 billion to discover drug targets for metabolic dysfunction-associated steatohepatitis and cardiomyopathies using insitro's Virtual Human AI platform. Insitro receives $40 million upfront and up to $1.46 billion in milestones plus royalties, while AstraZeneca advances any candidates through development. The deal adds to AstraZeneca's MASH work, which includes the Phase 1 anti-fibrotic asset AZD2389.
Why it matters
A large pharma-AI target discovery deal in MASH and cardiomyopathies, indications where AstraZeneca has recent setbacks.
Source: biospace.com · biospace.com